Mark J. O’Connor

21.3k total citations · 5 hit papers
119 papers, 13.7k citations indexed

About

Mark J. O’Connor is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Mark J. O’Connor has authored 119 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Oncology, 83 papers in Molecular Biology and 29 papers in Genetics. Recurrent topics in Mark J. O’Connor's work include DNA Repair Mechanisms (63 papers), PARP inhibition in cancer therapy (61 papers) and BRCA gene mutations in cancer (17 papers). Mark J. O’Connor is often cited by papers focused on DNA Repair Mechanisms (63 papers), PARP inhibition in cancer therapy (61 papers) and BRCA gene mutations in cancer (17 papers). Mark J. O’Connor collaborates with scholars based in United Kingdom, United States and Singapore. Mark J. O’Connor's co-authors include Alan Lau, Johann S. de Bono, Alan Ashworth, Andrew Tutt, Timothy A. Yap, Graeme C.M. Smith, James Carmichael, Peijun Wu, Helen Swaisland and Stan B. Kaye and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Mark J. O’Connor

114 papers receiving 13.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

2009 2.7k citations Timothy A. Yap, Andrew Tutt et al. profile →
Targeting the DNA Damage Response in Cancer

2015 1.1k citations Mark J. O’Connor profile →
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

2006 977 citations Nuala McCabe, Nicholas C. Turner et al. Cancer Research profile →
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

2008 762 citations Sven Rottenberg, Janneke E. Jaspers et al. profile →
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

2016 540 citations Mark J. O’Connor et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Mark J. O’Connor	9.0k	8.9k	2.0k	1.8k	1.3k	119	13.7k
Heidi L. Weiss	4.8k 0.5×	5.0k 0.6×	2.1k 1.1×	2.9k 1.6×	1.1k 0.9×	262	12.4k
Andrew K. Godwin	6.0k 0.7×	13.4k 1.5×	2.8k 1.4×	5.2k 2.9×	2.5k 1.9×	386	22.4k
Yun Yen	4.2k 0.5×	9.1k 1.0×	776 0.4×	3.5k 1.9×	1.4k 1.0×	369	15.2k
Ernst Lengyel	5.7k 0.6×	10.6k 1.2×	627 0.3×	7.8k 4.3×	1.4k 1.1×	190	18.7k
Peter M. Glazer	2.8k 0.3×	10.6k 1.2×	1.5k 0.7×	4.5k 2.5×	943 0.7×	247	14.0k
Pamela N. Münster	4.6k 0.5×	6.1k 0.7×	755 0.4×	1.2k 0.7×	1.9k 1.5×	307	11.4k
Jianhua Yu	5.5k 0.6×	6.3k 0.7×	1.8k 0.9×	2.3k 1.2×	620 0.5×	308	16.5k
Ena Wang	6.3k 0.7×	5.4k 0.6×	1.4k 0.7×	2.0k 1.1×	949 0.7×	260	14.2k
Kunle Odunsi	7.2k 0.8×	5.0k 0.6×	978 0.5×	2.1k 1.2×	1.5k 1.1×	370	15.5k
David J. Chen	5.7k 0.6×	15.0k 1.7×	1.2k 0.6×	3.5k 1.9×	1.7k 1.3×	189	17.9k

Countries citing papers authored by Mark J. O’Connor

Since Specialization

Citations

This map shows the geographic impact of Mark J. O’Connor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. O’Connor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. O’Connor more than expected).

Fields of papers citing papers by Mark J. O’Connor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. O’Connor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. O’Connor. The network helps show where Mark J. O’Connor may publish in the future.

Co-authorship network of co-authors of Mark J. O’Connor

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. O’Connor. A scholar is included among the top collaborators of Mark J. O’Connor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. O’Connor. Mark J. O’Connor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Burke, Martin C., Reinoud E. Knops, Vivek Y. Reddy, et al.. (2023). Initial Experience With Intercostal Insertion of an Extravascular ICD Lead Compatible With Existing Pulse Generators. Circulation Arrhythmia and Electrophysiology. 16(8). 421–432. 2 indexed citations

Teo, Zhi L., Mark J. O’Connor, Christopher Mintoff, et al.. (2023). Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer. npj Breast Cancer. 9(1). 68–68. 14 indexed citations

Thomson, John P., Graeme R. Grimes, Anderson T. Wang, et al.. (2022). Identifying and overcoming a mechanism of resistance to WEE1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells. European Journal of Gynaecological Oncology. 43(2). 183–183. 11 indexed citations

Muñoz‐Martínez, Francisco, Christelle de Renty, Mark J. O’Connor, et al.. (2021). Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress. Nucleic Acids Research. 49(15). 8665–8683. 35 indexed citations

Young, Lucy A., Christelle de Renty, Margaret H. Veldman-Jones, et al.. (2019). Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Cancer Research. 79(14). 3762–3775. 54 indexed citations

Pilié, Patrick G., Carl M. Gay, Lauren A. Byers, Mark J. O’Connor, & Timothy A. Yap. (2019). PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clinical Cancer Research. 25(13). 3759–3771. 244 indexed citations

Min, Ahrum, Hyemin Jang, Seongyeong Kim, et al.. (2018). Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response. Molecular Cancer Therapeutics. 17(12). 2507–2518. 15 indexed citations

Parsels, Leslie A., David Karnak, Joshua D. Parsels, et al.. (2017). PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors. Molecular Cancer Research. 16(2). 222–232. 98 indexed citations

Min, Ahrum, Seock‐Ah Im, Hyemin Jang, et al.. (2017). AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. Molecular Cancer Therapeutics. 16(4). 566–577. 105 indexed citations

10.

O’Connor, Lenka Oplustil, Stuart L. Rulten, Aaron Cranston, et al.. (2016). The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. Cancer Research. 76(20). 6084–6094. 60 indexed citations

11.

Naipal, Kishan A.T., Nicole S. Verkaik, Najim Ameziane, et al.. (2014). Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment. Clinical Cancer Research. 20(18). 4816–4826. 124 indexed citations

12.

Muhammad, Sajjad, Elizabeth Rosenberg, Jason M. Beckta, et al.. (2013). ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation. Clinical Cancer Research. 19(12). 3189–3200. 150 indexed citations

13.

Min, Ahrum, Seock‐Ah Im, Young‐Kwang Yoon, et al.. (2013). RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. Molecular Cancer Therapeutics. 12(6). 865–877. 109 indexed citations

14.

Jaspers, Janneke E., Ariena Kersbergen, Ute Boon, et al.. (2012). Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors. Cancer Discovery. 3(1). 68–81. 388 indexed citations

15.

Senra, Joana M., Brian A. Telfer, Cian M. McCrudden, et al.. (2011). Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft. Molecular Cancer Therapeutics. 10(10). 1949–1958. 155 indexed citations

16.

Williamson, Chris T., Huong Muzik, Ali G. Turhan, et al.. (2010). ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors. Molecular Cancer Therapeutics. 9(2). 347–357. 147 indexed citations

17.

McAlpine, Jessica N., Hui Xue, Jun Guan, et al.. (2010). Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts. Clinical Cancer Research. 17(4). 783–791. 52 indexed citations

18.

Hay, Trevor, James R. Matthews, Alan Lau, et al.. (2009). Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53 -Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin. Cancer Research. 69(9). 3850–3855. 94 indexed citations

19.

Golding, Sarah E., Elizabeth Rosenberg, Nicholas C.K. Valerie, et al.. (2009). Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Molecular Cancer Therapeutics. 8(10). 2894–2902. 285 indexed citations

20.

McCabe, Nuala, Nicholas C. Turner, Christopher J. Lord, et al.. (2006). Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition. Cancer Research. 66(16). 8109–8115. 977 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact